TUning the RiBOsome with Zikani Molecules- TURBO-ZM
We are committed to fully exploiting our platform to
develop novel Ribosome Modulating Agents (RMAs)
About Zikani Therapeutics
Zikani Therapeutics is using its innovative chemistry technology platform to develop novel Ribosome Modulating Agents (RMAs).
Zikani’s TURBO-ZM platform allows rapid synthesis of novel compounds that can be optimized to modulate the ribosome in a disease specific manner.
Become a Zikanian
Join the Zikani Team
Make a difference, and make it soon. Our groundbreaking technology provides the opportunity for rapid development of important new drugs. Come join a highly motivated and focused team.
Make a difference and, Make it Soon
Our Approach to Ribosome targeted drugs
Leveraging TURBO-ZM, a highly efficient chemistry platform, we are generating novel, orally bioavailable small-molecule RMAs that:
- Are functionally and structurally diverse
- Can be readily optimized for disease specificity
- Address substantial unmet needs
At Zikani Therapeutics, We have a team of experts on bringing on their years of experience on developing and commercializing therapies. Our team is dedicated to improve the life of patients by developing Novel Ribosome Modulating Agents (RMAs)
Let’s work together
At Zikani Therapeutics, we are eager to collaborate with academic institutions and other companies who are interested in the development of Ribosome Modulating Agents (RMAs) with a focus on treating patients that have currently limited options. We believe that collaborative alliances are the most effective way to develop new medicines. If you would like to discuss working together, we’d be delighted to speak with you.
Partner With Us
we’d be delighted to speak with you
Latest News & Events
Macrolide Pharmaceuticals Expands Leadership and Strengthens Expertise in Drug Development, Clinical Strategy, Finance and Business Development
Macrolide Pharmaceuticals, which is currently developing novel therapies to fight serious infections,
Macrolide Pharmaceuticals, a next-generation antibiotics company developing macrolides that are first-in-class with Gram-
Macrolide Pharmaceuticals Announces Up to $6.8 Million Award
from CARB-X to Develop Macrolide Antibiotics with Gram-Negative Activity
WATERTOWN, Mass. – March 26, 2018 – Macrolide Pharmaceuticals today
Call us now
We are here
480 Arsenal Way, Suite 130
Watertown, MA 02472
Drop us an email